Narcolepsy

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Tuesday, October 10, 2023
Congress, Neuroscience, BRT, Pharmacokinetics, Idiopathic hypersomnia, Cataplexy, Risk factor, ALKS, Safety, Wakefulness, Risk, Signs and symptoms, Model, OX2R, Investigational New Drug, Diagnosis, Pharmaceutical industry, Alkermes, Narcolepsy, Patient

DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy, at World Sleep Congress, taking place Oct. 20-25, 2023, in Rio de Janeiro. In an oral presentation, the company will present initial data from its ongoing phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia. This presentation will include initial clinical proof-of-concept data from the first cohort of four patients with narcolepsy type 1.

Key Points: 
  • — Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist —
    DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy, at World Sleep Congress, taking place Oct. 20-25, 2023, in Rio de Janeiro.
  • In an oral presentation, the company will present initial data from its ongoing phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia.
  • This presentation will include initial clinical proof-of-concept data from the first cohort of four patients with narcolepsy type 1.
  • We look forward to presenting data at the World Sleep Congress, including our first clinical data for ALKS 2680 in patients with narcolepsy."

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Tuesday, October 10, 2023
Congress, Neuroscience, BRT, Pharmacokinetics, Idiopathic hypersomnia, Cataplexy, Risk factor, ALKS, Safety, Wakefulness, Risk, Signs and symptoms, Model, OX2R, Investigational New Drug, Diagnosis, Pharmaceutical industry, Alkermes, Narcolepsy, Patient

DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy, at World Sleep Congress, taking place Oct. 20-25, 2023, in Rio de Janeiro. In an oral presentation, the company will present initial data from its ongoing phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia. This presentation will include initial clinical proof-of-concept data from the first cohort of four patients with narcolepsy type 1.

Key Points: 
  • — Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist —
    DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy, at World Sleep Congress, taking place Oct. 20-25, 2023, in Rio de Janeiro.
  • In an oral presentation, the company will present initial data from its ongoing phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia.
  • This presentation will include initial clinical proof-of-concept data from the first cohort of four patients with narcolepsy type 1.
  • We look forward to presenting data at the World Sleep Congress, including our first clinical data for ALKS 2680 in patients with narcolepsy."

Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

Retrieved on: 
Tuesday, October 3, 2023
Data management, DevOps, BS, GSK plc, Drug development, Senior, Hematology, Drug, CNTA, Narcolepsy, Oncology, Merck & Co., Takeda Oncology, Medical director, MD, Patient, Haemophilia, Internal medicine, Catholic University College, Kensington, Merck, Cornell University, Society, Pharmaceutical industry, Nursing

“April has an impressive track record in global clinical trial strategy and execution across all stages of drug development.

Key Points: 
  • “April has an impressive track record in global clinical trial strategy and execution across all stages of drug development.
  • Prior to joining Centessa, Ms. Dovholuk was Senior Vice President, Clinical Development Operations at Replimune where she led teams in clinical operations, data management, process improvement and CRO management.
  • She most recently served as Senior Vice President, Clinical Development and Operations at Mersana Therapeutics Inc.
  • Previously, Dr. Im was Clinical Development Lead and Senior Medical Director at Tesaro Inc., an oncology-focused company that was later acquired by GlaxoSmithKline plc.

Adaptive Immune Response in Narcolepsy Type 1, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 27, 2023
NT1, Myenteric plexus, Stanford University School of Medicine, Sleep, Somnolence, Muscle weakness, CSF, Narcolepsy, Emotion, Patient, HLA, RNA, Cerebrospinal fluid, Vaccine

TORONTO, Sept. 27, 2023 /PRNewswire-PRWeb/ -- Narcolepsy — a chronic neurological disorder — affects the brain's capability in controlling the sleep-wake cycles. People affected with narcolepsy might feel rested after waking up, but then feel very sleepy throughout the day. Most people with narcolepsy also experience interrupted and uneven sleep that can involve waking up repeatedly during the night.

Key Points: 
  • In this free webinar, gain insights into an overview of adaptive immune response in narcolepsy.
  • There are two main types of narcolepsy: type 1 and type 2.
  • People with narcolepsy type 2 experience extreme daytime sleepiness but usually don't experience muscle weakness activated by emotions.
  • In this webinar, the featured speaker will share and discuss the following:
    Join this webinar to gain insights on the overview of the adaptive immune response in narcolepsy type 1.

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

Retrieved on: 
Thursday, September 21, 2023
Central nervous system, Education, Public, Research, CNS, Science, Thought, Organization, National Sleep Foundation, Patient, Central nervous system disease, Risk, Mortality, Ageing, Health, Conference, Therapy, Sleep, Disease, Pharmaceutical industry, Narcolepsy

In support of World Narcolepsy Day, Axsome is sponsoring several awareness events:

Key Points: 
  • In support of World Narcolepsy Day, Axsome is sponsoring several awareness events:
    On Sept. 21 at 6 p.m. Eastern Time, Axsome is sponsoring a virtual panel where an international group of experts will discuss narcolepsy around the world, organized by Wake Up Narcolepsy.
  • Axsome is committed to developing innovative therapies that make an impact on the lives of people suffering from CNS disorders, including those with narcolepsy and other sleep disorders.
  • For more information about narcolepsy, World Narcolepsy Day, as well as additional resources for patients, please learn more about the following organizations and their affiliates:
    Wake Up Narcolepsy ( https://www.wakeupnarcolepsy.org/ ): a nonprofit organization dedicated to driving narcolepsy awareness, education and research towards improved treatments and a cure.
  • Narcolepsy Network ( https://narcolepsynetwork.org/ ): is a national patient support organization dedicated to education, support and assistance, advocacy, and resources for people with narcolepsy.

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

Retrieved on: 
Monday, September 11, 2023
Psych, Abstract, Abstract (summary), Bachelor of Medicine, Bachelor of Surgery, Narcolepsy, Depression, University, Idiopathic hypersomnia, Magnesium, Anxiety, Safety, Efficacy, Quality of life, Medical school, Research, Mental health, Disruption, Calcium, DSM-IV codes, Literature, Patient, Sleep disorder, Physician, Psychiatry, FCCP, MRCPCH, Jazz Pharmaceuticals, Potassium, Pharmaceutical industry, Sleep, Gamma-Hydroxybutyric acid, MD, Medicine

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy. Oxybate is the active ingredient in Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution.

Key Points: 
  • Review of multiple clinical trials provided a comprehensive analysis showing that oxybate improves sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy, independent of once- or twice-nightly dosing
    DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023.
  • One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy.
  • The review found that oxybate improved measures of sleep architecture and disrupted nighttime sleep in narcolepsy patients, independent of dosing regimen or prior oxybate experience.
  • "Idiopathic hypersomnia has a profound impact on those who live with this debilitating sleep disorder," said Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

Retrieved on: 
Monday, September 11, 2023
Psych, Abstract, Abstract (summary), Bachelor of Medicine, Bachelor of Surgery, Narcolepsy, Depression, University, Idiopathic hypersomnia, Magnesium, Anxiety, Safety, Efficacy, Quality of life, Medical school, Research, Mental health, Disruption, Calcium, DSM-IV codes, Literature, Patient, Sleep disorder, Physician, Psychiatry, FCCP, MRCPCH, Jazz Pharmaceuticals, Potassium, Pharmaceutical industry, Sleep, Gamma-Hydroxybutyric acid, MD, Medicine

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy. Oxybate is the active ingredient in Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution.

Key Points: 
  • Review of multiple clinical trials provided a comprehensive analysis showing that oxybate improves sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy, independent of once- or twice-nightly dosing
    DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023.
  • One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy.
  • The review found that oxybate improved measures of sleep architecture and disrupted nighttime sleep in narcolepsy patients, independent of dosing regimen or prior oxybate experience.
  • "Idiopathic hypersomnia has a profound impact on those who live with this debilitating sleep disorder," said Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

Retrieved on: 
Monday, September 11, 2023
Psych, PANSS, Olanzapine, Wellness, Bipolar I disorder, Addiction, Paliperidone palmitate, COVID-19, Humanism, ARISTADA, Observational study, Signs and symptoms, Initiation, Lais, Research, Meta-analysis, Patient, Diagnosis, ALKS, Congress, Neuroscience, Alkermes, Aripiprazole lauroxil, Post hoc analysis, Conditional sentence, Clinical, Human, Treatment, Weight gain, Pharmaceutical industry, Paliperidone, Narcolepsy, Schizophrenia

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville. This research reflects the company's continued commitment to improving care for, and understanding the unique needs of, people living with serious chronic diseases.

Key Points: 
  • — Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy —
    DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville.
  • This research reflects the company's continued commitment to improving care for, and understanding the unique needs of, people living with serious chronic diseases.
  • "Psych Congress offers an important opportunity for scientific exchange and information sharing as we seek to advance care for people living with serious, complex diseases.
  • This year's presentations further reinforce Alkermes' leadership and experience in the field of neuroscience," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes.

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

Retrieved on: 
Monday, September 11, 2023
Psych, PANSS, Olanzapine, Wellness, Bipolar I disorder, Addiction, Paliperidone palmitate, COVID-19, Humanism, ARISTADA, Observational study, Signs and symptoms, Initiation, Lais, Research, Meta-analysis, Patient, Diagnosis, ALKS, Congress, Neuroscience, Alkermes, Aripiprazole lauroxil, Post hoc analysis, Conditional sentence, Clinical, Human, Treatment, Weight gain, Pharmaceutical industry, Paliperidone, Narcolepsy, Schizophrenia

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville. This research reflects the company's continued commitment to improving care for, and understanding the unique needs of, people living with serious chronic diseases.

Key Points: 
  • — Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy —
    DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville.
  • This research reflects the company's continued commitment to improving care for, and understanding the unique needs of, people living with serious chronic diseases.
  • "Psych Congress offers an important opportunity for scientific exchange and information sharing as we seek to advance care for people living with serious, complex diseases.
  • This year's presentations further reinforce Alkermes' leadership and experience in the field of neuroscience," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes.

Short naps can improve memory, increase productivity, reduce stress and promote a healthier heart

Retrieved on: 
Monday, August 28, 2023
Blood pressure, Mental toughness, Music, Headache, Siderian, Education, Caffeine, Life, Alertness, Mood, Narcolepsy, Workplace, Overalls, Sleep, Ageing, Nap, Chronic pain, Sleep apnea, Brain, Attention, Golf, Creativity, Pain, Adenosine, Insomnia, Orofacial pain, Incidence, Frasier, Metabolic syndrome, Risk, Sleep disorder, Lunch, Somnolence, Efficiency, Research, Memory, Paint, Leather

While some people view napping as a luxurious indulgence, others see it as a way to maintain alertness and well-being.

Key Points: 
  • While some people view napping as a luxurious indulgence, others see it as a way to maintain alertness and well-being.
  • My training involved all aspects of sleep, especially sleep breathing disorders, insomnia and sleep-related movement disorders.

An abundance of health benefits

    • Short naps can boost mental functioning and memory, as well as improve alertness, attention and reaction time.
    • Because napping seems to improve creative thinking, some companies have attempted to harness this by introducing napping rooms into the workplace.
    • This is because these memories or skills become consolidated in the brain during sleep, whether at night or while napping.
    • Interestingly, many people overestimate their time awake when trying to sleep and underestimate the time they actually spent sleeping.

Napping can have drawbacks

    • One condition associated with napping longer than 30 minutes is sleep inertia – the grogginess and disorientation that people sometime experience after waking from a longer nap.
    • This can impair cognitive function from several minutes up to half an hour.
    • But it is important to note that caffeine is not a substitute for sleep.
    • This could be related to more pain or other health factors that will interfere with sleep, sleep altering medications and altered sleep rhythms seen with aging.

Best practices

    • If you’re struggling with daytime sleepiness, it’s best to address the root cause rather than relying solely on napping.
    • Reducing caffeine consumption, maintaining a regular sleep schedule and getting adequate nighttime sleep are essential steps to reduce daytime sleepiness.